All In Biotech

Drug Trial Radar · NCT04960709

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 712 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

712

Actual

Start

Aug 5, 2021

Primary completion

Mar 2, 2026

Study completion Sep 8, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplatin based chemotherapy Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or the duplet combination of Durvalumab and Enfortumab vedotin in terms of efficacy and safety compared to the current Standard Of Care (SOC). VOLGA trial consists of two parts: Safety Run-In and Main Study. In total the study aims to enroll approximately 677 patients, who will receive triplet combination, duplet combination or currently approved SOC in the main study. In the main part of the trial there is two out of three chances of being on a treatment arm and the treatment is assigned at random by a computer system. In this trial patients in the two treatment arms will receive either 3 cycles of neoadjuvant Durvalumab + Enfortumab Vedotin and 2 cycles of Tremelimumab or Durvalumab + Enfortumab vedotin and after surgery both treatment arms will receive either adjuvant Durvalumab or adjuvant Durvalumab and 1 cycle of Tremelimumab.

Conditions

  • Muscle Invasive Bladder Cancer

Interventions

  • DurvalumabDrug

    Anti- PD-L1 Antibody

  • TremelimumabDrug

    Human IgG2 mAb

  • Enfortumab VedotinDrug

    Nectin-4-directed antibody and microtubule inhibitor conjugate

  • Radical CystectomyProcedure

    For cisplatin-ineligible or cisplatin-refusal patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability as evaluated by adverse events occurring throughout the study (Safety Run-In part)Time frame: At completion of study treatment by the last patient and at 3 months.
  2. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (blood pressure in mmHg) (Safety Run-In part)Time frame: Up to 84 months
  3. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (pulse rate) in beats per minute (Safety Run-In part)Time frame: Up to 84 months
  4. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (respiration rate) in breaths per minute (Safety Run-In part)Time frame: Up to 84 months
  5. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by vital signs (temperature) in degrees Celsius (Safety Run-In part)Time frame: Up to 84 months
  6. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by abnormality in clinical chemistry by liver function (Safety Run-In part)Time frame: Up to 84 months
  7. Safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin or who refuse cisplatin as assessed by abnormality in clinical chemistry by kidney function (Safety Run-In part)Time frame: Up to 84 months
  8. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by abnormality in clinical chemistry by thyroid function (Safety Run-In part)Time frame: Up to 84 months
  9. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as assessed by abnormality in haematology (Safety Run-In part)Time frame: Up to 84 months
  10. To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC who are ineligible for cisplatin as as assessed by ECG (pulse rate) (Safety Run-In part)Time frame: Up to 84 months
  11. Changes in WHO/ECOG performance status (Safety Run-In part)Time frame: Up to 84 months
  12. Compare efficacy of durvalumab + tremelimumab + EV (Arm 1) relative to cystectomy (Arm 3) and durvalumab + EV (Arm 2) relative to cystectomy (Arm 3) on EFS (Main Study)Time frame: Up to 3 years

Locations

196 sites in 25 countries. Site status is shown where the registry gives one.

  • Research Site

    Orange, California

  • Research Site

    Santa Monica, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Fort Myers, Florida

  • Research Site

    Coeur d'Alene, Idaho

  • Research Site

    Maywood, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Iowa City, Iowa

  • Research Site

    Louisville, Kentucky

  • Research Site

    Scarborough, Maine

  • Research Site

    Boston, Massachusetts

  • Research Site

    Brighton, Michigan

  • Research Site

    Jackson, Mississippi

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Saddle Brook, New Jersey

  • Research Site

    Brooklyn, New York

  • Research Site

    Buffalo, New York

  • Research Site

    New York, New York

  • Research Site

    Syracuse, New York

  • Research Site

    Portland, Oregon

  • Research Site

    Hershey, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Fort Worth, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Irving, Texas

  • Research Site

    Norfolk, Virginia

  • Research Site

    Spokane, Washington

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Pergamino, Argentina

  • Research Site

    Graz, Austria

  • Research Site

    Krems, Austria

  • Research Site

    Linz, Austria

  • Research Site

    Vienna, Austria

Showing 40 of 196 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.